Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy : a real-world, nationwide cohort of patients with inflammatory bowel diseases. / Attauabi, Mohamed; Höglund, Camilla; Fassov, Janne; Pedersen, Kenneth Bo; Hansen, Heidi Bansholm; Wildt, Signe; Jensen, Michael Dam; Neumann, Anders; Lind, Cecilie; Jacobsen, Henrik Albaek; Popa, Ana Maria; Kjeldsen, Jens; Pedersen, Natalia; Molazahi, Akbar; Haderslev, Kent; Aalykke, Claus; Knudsen, Torben; Cebula, Wojciech; Munkholm, Pia; Bendtsen, Flemming; Seidelin, Jakob Benedict; Burisch, Johan.

I: Scandinavian Journal of Gastroenterology, Bind 56, Nr. 9, 2021, s. 1040-1048.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Attauabi, M, Höglund, C, Fassov, J, Pedersen, KB, Hansen, HB, Wildt, S, Jensen, MD, Neumann, A, Lind, C, Jacobsen, HA, Popa, AM, Kjeldsen, J, Pedersen, N, Molazahi, A, Haderslev, K, Aalykke, C, Knudsen, T, Cebula, W, Munkholm, P, Bendtsen, F, Seidelin, JB & Burisch, J 2021, 'Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases', Scandinavian Journal of Gastroenterology, bind 56, nr. 9, s. 1040-1048. https://doi.org/10.1080/00365521.2021.1946588

APA

Attauabi, M., Höglund, C., Fassov, J., Pedersen, K. B., Hansen, H. B., Wildt, S., Jensen, M. D., Neumann, A., Lind, C., Jacobsen, H. A., Popa, A. M., Kjeldsen, J., Pedersen, N., Molazahi, A., Haderslev, K., Aalykke, C., Knudsen, T., Cebula, W., Munkholm, P., ... Burisch, J. (2021). Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scandinavian Journal of Gastroenterology, 56(9), 1040-1048. https://doi.org/10.1080/00365521.2021.1946588

Vancouver

Attauabi M, Höglund C, Fassov J, Pedersen KB, Hansen HB, Wildt S o.a. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scandinavian Journal of Gastroenterology. 2021;56(9):1040-1048. https://doi.org/10.1080/00365521.2021.1946588

Author

Attauabi, Mohamed ; Höglund, Camilla ; Fassov, Janne ; Pedersen, Kenneth Bo ; Hansen, Heidi Bansholm ; Wildt, Signe ; Jensen, Michael Dam ; Neumann, Anders ; Lind, Cecilie ; Jacobsen, Henrik Albaek ; Popa, Ana Maria ; Kjeldsen, Jens ; Pedersen, Natalia ; Molazahi, Akbar ; Haderslev, Kent ; Aalykke, Claus ; Knudsen, Torben ; Cebula, Wojciech ; Munkholm, Pia ; Bendtsen, Flemming ; Seidelin, Jakob Benedict ; Burisch, Johan. / Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy : a real-world, nationwide cohort of patients with inflammatory bowel diseases. I: Scandinavian Journal of Gastroenterology. 2021 ; Bind 56, Nr. 9. s. 1040-1048.

Bibtex

@article{a4db60fbcf6d4170a48bf8a16b48879c,
title = "Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases",
abstract = "Background: Data from real-life populations about vedolizumab as first-line biological therapy for ulcerative colitis (UC) and Crohn{\textquoteright}s disease (CD) are emerging. Objective: To investigate the efficacy and safety of vedolizumab in bio-na{\"i}ve patients with UC and CD. Methods: A Danish nationwide cohort study was conducted between November 2014 and November 2019. Primary outcomes were clinical remission, steroid-free clinical remission, and sustained clinical remission from weeks 14 through 52. Results: The study included 56 patients (UC:31, CD:25) who initiated treatment with vedolizumab mainly because of contraindications to anti-TNFs, of whom 54.8 and 24.0%, respectively received systemic steroids at the initiation. Rates of clinical remission at weeks 6, 14, and 52 were 32.0, 48.0, and 40.0%, respectively, in UC, and 36.8, 36.8, and 47.4% in CD. Steroid-free clinical remission at week 52 was achieved among 36.0 and 47.4% of UC and CD patients, while sustained clinical remission was achieved in 32.0 and 36.8%. Lack of remission was associated with being female (68.8 vs. 11.1%, p =.01) in UC and non‐structuring, non‐penetrating behavior in CD (90.0 vs. 44.4%, p =.03); however, this was not confirmed in multivariate analysis. Discontinuation due to primary non-response occurred in 20.0 and 5.3% of UC and CD patients, respectively, while rates of secondary loss of response were 12.0 and 5.3% after 52 weeks of follow-up. Vedolizumab was well-tolerated as only one UC patient experienced a serious adverse event. Conclusion: Vedolizumab is effective in the achievement of short-term, long-term, and steroid-free clinical remission in bio-na{\"i}ve UC and CD patients.",
keywords = "bio-na{\"i}ve, Crohn{\textquoteright}s disease, efficacy, first-line biologics, Inflammatory bowel disease, nationwide, population-based, real-world, safety, ulcerative colitis, vedolizumab",
author = "Mohamed Attauabi and Camilla H{\"o}glund and Janne Fassov and Pedersen, {Kenneth Bo} and Hansen, {Heidi Bansholm} and Signe Wildt and Jensen, {Michael Dam} and Anders Neumann and Cecilie Lind and Jacobsen, {Henrik Albaek} and Popa, {Ana Maria} and Jens Kjeldsen and Natalia Pedersen and Akbar Molazahi and Kent Haderslev and Claus Aalykke and Torben Knudsen and Wojciech Cebula and Pia Munkholm and Flemming Bendtsen and Seidelin, {Jakob Benedict} and Johan Burisch",
note = "Publisher Copyright: {\textcopyright} 2021 Informa UK Limited, trading as Taylor & Francis Group.",
year = "2021",
doi = "10.1080/00365521.2021.1946588",
language = "English",
volume = "56",
pages = "1040--1048",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Taylor & Francis",
number = "9",

}

RIS

TY - JOUR

T1 - Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy

T2 - a real-world, nationwide cohort of patients with inflammatory bowel diseases

AU - Attauabi, Mohamed

AU - Höglund, Camilla

AU - Fassov, Janne

AU - Pedersen, Kenneth Bo

AU - Hansen, Heidi Bansholm

AU - Wildt, Signe

AU - Jensen, Michael Dam

AU - Neumann, Anders

AU - Lind, Cecilie

AU - Jacobsen, Henrik Albaek

AU - Popa, Ana Maria

AU - Kjeldsen, Jens

AU - Pedersen, Natalia

AU - Molazahi, Akbar

AU - Haderslev, Kent

AU - Aalykke, Claus

AU - Knudsen, Torben

AU - Cebula, Wojciech

AU - Munkholm, Pia

AU - Bendtsen, Flemming

AU - Seidelin, Jakob Benedict

AU - Burisch, Johan

N1 - Publisher Copyright: © 2021 Informa UK Limited, trading as Taylor & Francis Group.

PY - 2021

Y1 - 2021

N2 - Background: Data from real-life populations about vedolizumab as first-line biological therapy for ulcerative colitis (UC) and Crohn’s disease (CD) are emerging. Objective: To investigate the efficacy and safety of vedolizumab in bio-naïve patients with UC and CD. Methods: A Danish nationwide cohort study was conducted between November 2014 and November 2019. Primary outcomes were clinical remission, steroid-free clinical remission, and sustained clinical remission from weeks 14 through 52. Results: The study included 56 patients (UC:31, CD:25) who initiated treatment with vedolizumab mainly because of contraindications to anti-TNFs, of whom 54.8 and 24.0%, respectively received systemic steroids at the initiation. Rates of clinical remission at weeks 6, 14, and 52 were 32.0, 48.0, and 40.0%, respectively, in UC, and 36.8, 36.8, and 47.4% in CD. Steroid-free clinical remission at week 52 was achieved among 36.0 and 47.4% of UC and CD patients, while sustained clinical remission was achieved in 32.0 and 36.8%. Lack of remission was associated with being female (68.8 vs. 11.1%, p =.01) in UC and non‐structuring, non‐penetrating behavior in CD (90.0 vs. 44.4%, p =.03); however, this was not confirmed in multivariate analysis. Discontinuation due to primary non-response occurred in 20.0 and 5.3% of UC and CD patients, respectively, while rates of secondary loss of response were 12.0 and 5.3% after 52 weeks of follow-up. Vedolizumab was well-tolerated as only one UC patient experienced a serious adverse event. Conclusion: Vedolizumab is effective in the achievement of short-term, long-term, and steroid-free clinical remission in bio-naïve UC and CD patients.

AB - Background: Data from real-life populations about vedolizumab as first-line biological therapy for ulcerative colitis (UC) and Crohn’s disease (CD) are emerging. Objective: To investigate the efficacy and safety of vedolizumab in bio-naïve patients with UC and CD. Methods: A Danish nationwide cohort study was conducted between November 2014 and November 2019. Primary outcomes were clinical remission, steroid-free clinical remission, and sustained clinical remission from weeks 14 through 52. Results: The study included 56 patients (UC:31, CD:25) who initiated treatment with vedolizumab mainly because of contraindications to anti-TNFs, of whom 54.8 and 24.0%, respectively received systemic steroids at the initiation. Rates of clinical remission at weeks 6, 14, and 52 were 32.0, 48.0, and 40.0%, respectively, in UC, and 36.8, 36.8, and 47.4% in CD. Steroid-free clinical remission at week 52 was achieved among 36.0 and 47.4% of UC and CD patients, while sustained clinical remission was achieved in 32.0 and 36.8%. Lack of remission was associated with being female (68.8 vs. 11.1%, p =.01) in UC and non‐structuring, non‐penetrating behavior in CD (90.0 vs. 44.4%, p =.03); however, this was not confirmed in multivariate analysis. Discontinuation due to primary non-response occurred in 20.0 and 5.3% of UC and CD patients, respectively, while rates of secondary loss of response were 12.0 and 5.3% after 52 weeks of follow-up. Vedolizumab was well-tolerated as only one UC patient experienced a serious adverse event. Conclusion: Vedolizumab is effective in the achievement of short-term, long-term, and steroid-free clinical remission in bio-naïve UC and CD patients.

KW - bio-naïve

KW - Crohn’s disease

KW - efficacy

KW - first-line biologics

KW - Inflammatory bowel disease

KW - nationwide

KW - population-based

KW - real-world

KW - safety

KW - ulcerative colitis

KW - vedolizumab

U2 - 10.1080/00365521.2021.1946588

DO - 10.1080/00365521.2021.1946588

M3 - Journal article

C2 - 34224299

AN - SCOPUS:85109690316

VL - 56

SP - 1040

EP - 1048

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 9

ER -

ID: 276082444